한빛사논문
- 조회420
Seung Hun Park1,2, Richard S. Kim1, Wesly R. Stiles1, Minjoo Jo1, Sunghoon Rho1, Yoonji Baek1, Jonghan Kim3, Moon Suk Kim2*, Homan Kang1,*, and Hak Soo Choi1,*
1Gordon Center for Medical Imaging, Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, United States 2Department of Molecular Science and Technology, Ajou University, Suwon16499, South Korea 3Department of Biomedical & Nutritional Sciences, Zuckerberg College of Health Sciences, University of Massachusetts, Lowell, MA 01854, United States
*Corresponding author.
Abstract
Deferoxamine (DFO) is an FDA-approved iron-chelating agent which shows good therapeutic efficacy, however, its short blood half-life presents challenges such as the need for repeated injections or continuous infusions. Considering the lifelong need of chelating agents for iron overload patients, a sustained-release formulation that can reduce the number of chelator administrations is essential. Here, injectable hydrogel formulations prepared by integrating crosslinked hyaluronic acid into Pluronic F127 for an extended release of DFO nanochelators are reported. The subcutaneously injected hydrogel shows a thermosensitive sol–gel transition at physiological body temperature and provides a prolonged release of renal clearable nanochelators over 2 weeks, resulting in a half-life 47-fold longer than that of the nanochelator alone. In addition, no chronic toxicity of the nanochelator-loaded hydrogel is confirmed by biochemical and histological analyses. This injectable hydrogel formulation with DFO nanochelators has the potential to be a promising formulation for the treatment of iron overload disorders.
논문정보
- Research article
- 2022년 03월 (BRIC 등록일 2022-04-04)
- 국내(교신)+국외 연구진
- 바이오·의료융합 > 바이오센싱 및 나노바이오물질
댓글 작성 로그인
팝업 닫기관련 링크
연구자 ID
관련분야 연구자보기
소속기관 논문보기
관련분야 논문보기
